A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Also Known As:
Networked: 41436 relevant articles (2260 outcomes, 5063 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Lymphoma (Lymphomas)
3. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
4. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)


1. Kantarjian, Hagop: 81 articles (07/2015 - 03/2002)
2. Grant, Steven: 76 articles (12/2015 - 01/2002)
3. Larson, Richard A: 68 articles (12/2015 - 03/2002)
4. Chung, Jing-Gung: 58 articles (11/2015 - 09/2003)
5. Marcucci, Guido: 55 articles (11/2015 - 02/2002)
6. Cortes, Jorge: 55 articles (08/2015 - 03/2002)
7. Andreeff, Michael: 55 articles (07/2015 - 02/2002)
8. Choi, Yung Hyun: 50 articles (11/2015 - 05/2005)
9. Dent, Paul: 49 articles (10/2013 - 01/2002)
10. Kantarjian, Hagop M: 48 articles (09/2015 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Leukemia:
1. Cytarabine (Cytosar-U)FDA LinkGeneric
2. imatinib (Gleevec)FDA Link
3. AntigensIBA
4. Cyclophosphamide (Cytoxan)FDA LinkGeneric
5. Methotrexate (Mexate)FDA LinkGeneric
6. Tretinoin (Retinoic Acid)FDA LinkGeneric
7. Interleukin-2 (IL2)IBA
12/01/1997 - "A similar phase I trial of IL-2 after alloBMT was also performed in children with acute leukemia beyond first complete remission. "
01/01/1989 - "In the current study we used the therapy of established murine leukemia to identify the lymphocyte subsets responsible for toxicity and for therapeutic efficacy of high-dose IL-2. "
05/01/1997 - "Adoptive transfer of CD3AK cells with low dose rIL-2 into the P 388 mice significantly enhanced the splenocyte proliferation (SP) induced by Con A, the NK cell activity and the splenocytic IL-2 production and prolonged their survival (45.19%); CTX (200 mg/kg) alone prolonged the survival of P 388-bearing mice (29.90%), but further decreased the immunodeficiency; combination of CTX and CD3AK passive transfer could prevent the reduction of SP, NK activity and IL-2 production in the leukemic mice and prolonged the survival (59.45%), combination of KSC and adoptively transfected CD2AK cells and/or CTX had a much better therapeutic efficacy for P 388 murine leukemia, 12.50%-75.00% of the leukemic mice were cured. "
01/01/1989 - "Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia."
09/01/1991 - "Anti-CD3 + IL-2 activated cells from patients with ALL and NHL who had received autologous BMT and cells from patients with leukemia who underwent allogeneic BMT were more effective in lysing the natural killer (NK) sensitive target, K562, and the NK-resistant target, Daudi, compared with controls. "
8. Etoposide (VP 16)FDA LinkGeneric
9. Doxorubicin (Adriamycin)FDA LinkGeneric
10. Vincristine (Oncovin)FDA LinkGeneric

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Transplants (Transplant)
3. Bone Marrow Transplantation (Transplantation, Bone Marrow)
4. Transplantation (Transplant Recipients)
5. Hematopoietic Stem Cell Transplantation